Dear Investors,
Long-acting injectable treatments offer an opportunity to improve access, adherence, and patient experience. Frenelle is applying its proprietary Faros™ drug-delivery technology to one of healthcare’s most significant unmet needs: Opioid Use Disorder.
Join Opus8 and New York Private Equity Forums (NYPEF) for an exclusive investor briefing featuring Frenelle PBC and FRN01, a 30-day subcutaneous buprenorphine injection designed to provide sustained OUD treatment with a more patient-friendly injection experience.
Why Investors Are Taking Notice
$1.2B+ Market — The global long-acting injectable buprenorphine market exceeded $1.2B in 2025, while long-acting treatment remains underpenetrated among patients receiving OUD treatment.
Differentiated Approach — FRN01 is designed to address key barriers associated with existing long-acting products, including injection-site pain, cost, and access.
Promising Preclinical Results — Recent PK and toxicology work demonstrated sustained drug levels over 30 days, low burst release, and a clean toxicology profile.
Experienced Team + Mayo Clinic — Frenelle combines an experienced pharmaceutical development team with Mayo Clinic addiction medicine expertise.
